Ultimovacs ASA (ULTI) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.299x

Based on the latest financial reports, Ultimovacs ASA (ULTI) has a cash flow conversion efficiency ratio of -0.299x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-24.70 Million ≈ $-2.60 Million USD) by net assets (Nkr82.67 Million ≈ $8.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ULTI stock market capitalisation for the company's overall valuation and market capitalisation.

Ultimovacs ASA - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Ultimovacs ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ultimovacs ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ultimovacs ASA ranked by their cash flow conversion efficiency. See ULTI operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Harbour Energy PLC LSE:HBR	0.167x
Online Brands Nordic AB ST:OBAB	-0.081x
Sunny Elec KO:004770	0.021x
eXoZymes, Inc. NASDAQ:EXOZ	-0.998x
meerecompany Incorporated KQ:049950	-0.118x
Dominari Holdings Inc. NASDAQ:DOMH	-0.917x
OFS Capital Corp NASDAQ:OFS	0.154x
Roundtop Machinery Industries Co Ltd TW:1540	0.023x

Annual Cash Flow Conversion Efficiency for Ultimovacs ASA (2016–2024)

The table below shows the annual cash flow conversion efficiency of Ultimovacs ASA from 2016 to 2024. View Ultimovacs ASA stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr82.67 Million ≈ $8.70 Million	Nkr-163.40 Million ≈ $-17.19 Million	-1.977x	-190.92%
2023-12-31	Nkr279.39 Million ≈ $29.40 Million	Nkr-189.83 Million ≈ $-19.98 Million	-0.679x	-82.06%
2022-12-31	Nkr449.35 Million ≈ $47.28 Million	Nkr-167.69 Million ≈ $-17.65 Million	-0.373x	-75.92%
2021-12-31	Nkr593.15 Million ≈ $62.42 Million	Nkr-125.83 Million ≈ $-13.24 Million	-0.212x	+4.27%
2020-12-31	Nkr488.38 Million ≈ $51.39 Million	Nkr-108.22 Million ≈ $-11.39 Million	-0.222x	-56.42%
2019-12-31	Nkr444.63 Million ≈ $46.79 Million	Nkr-62.99 Million ≈ $-6.63 Million	-0.142x	+55.04%
2018-12-31	Nkr159.90 Million ≈ $16.83 Million	Nkr-50.39 Million ≈ $-5.30 Million	-0.315x	-92.70%
2017-12-31	Nkr166.48 Million ≈ $17.52 Million	Nkr-27.23 Million ≈ $-2.86 Million	-0.164x	+60.13%
2016-12-31	Nkr75.82 Million ≈ $7.98 Million	Nkr-31.10 Million ≈ $-3.27 Million	-0.410x	--

About Ultimovacs ASA

OL:ULTI Norway Biotechnology

Market Cap

$52.14 Million

Nkr495.45 Million NOK

Market Cap Rank

#21822 Global

#197 in Norway

Share Price

Nkr14.40

Change (1 day)

+0.00%

52-Week Range

Nkr14.40 - Nkr14.40

All Time High

Nkr162.00